BioMerieux SA
BIM: XPAR (FRA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€383.00 | Tmcypc | Tnmgxxqfq |
BioMerieux: Leader in Microbiology Testing and Syndromic Molecular Testing
Business Strategy and Outlook
BioMerieux is a niche player in the fragmented in vitro diagnostic market and has specialty positioning in clinical and industrial microbiology and multiplex molecular diagnostics, or syndromic testing. The company also sells immunoassays. With over EUR 3.6 billion in sales, BioMerieux is one of the largest global mid-cap diagnostic companies.